الاتحاد الأوروبي - الرومانية - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantle-cell - agenți antineoplazici - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

الاتحاد الأوروبي - الرومانية - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - agenți antineoplazici - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

الاتحاد الأوروبي - الرومانية - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - agenți antineoplazici - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

رومانيا - الرومانية - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

synthon hispania s.l. - spania - lenalidomidum - caps. - 10mg - imunosupresoare alte imunosupresoare

رومانيا - الرومانية - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

synthon hispania s.l. - spania - lenalidomidum - caps. - 15mg - imunosupresoare alte imunosupresoare

رومانيا - الرومانية - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

synthon hispania s.l. - spania - lenalidomidum - caps. - 25mg - imunosupresoare alte imunosupresoare

رومانيا - الرومانية - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

synthon hispania s.l. - spania - lenalidomidum - caps. - 5mg - imunosupresoare alte imunosupresoare

رومانيا - الرومانية - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

accord healthcare polska sp. z. o.o. - polonia - temsirolimusum - conc. si solv. pt. sol. perf. - 30mg - inhibitori de protein-kinaza

رومانيا - الرومانية - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

apl swift services (malta) ltd. - malta - lenalidomidum - caps. - 10mg - imunosupresoare alte imunosupresoare

رومانيا - الرومانية - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

apl swift services (malta) ltd. - malta - lenalidomidum - caps. - 15mg - imunosupresoare alte imunosupresoare